AIV Logo AIV Assistant

Loading...

Earnings Recaps

Browse reported earnings of the most popular stocks

34 companies Today
ADC Therapeutics SA logo
AD
ADC Therapeutics SA
ADCT
Q3 2025
Reported:

ADC Therapeutics reported steady net product revenues of $15.8 million in Q3 2025, reflecting consistent demand for its lead product, ZENLATA, while positioning for future growth through ongoing clinical trials and recent financing.

Key takeaways
  • Net product revenues were stable, matching quarterly run rates from the previous two years.
  • Secured a $60 million private placement, extending the cash runway into 2028.
  • Multiple ongoing clinical trials for ZENLATA are expected to bolster its market position, with potential expansions into earlier treatment lines and additional lymphoma types.
  • Anticipation for upcoming data releases from key trials, including LOTUS V and LOTUS seven, which could enhance revenue projections significantly.
  • Long-term peak annual revenue for ZENLATA is estimated between $600 million and $1 billion, contingent on successful trial outcomes and market expansion.
More info
Amphastar Pharmaceuticals, Inc. logo
AM
Amphastar Pharmaceuticals, Inc.
AMPH
Q3 2025
Reported:

Amphastar Pharmaceuticals reported solid third-quarter results, achieving net revenues of $191.8 million and a 14% year-over-year sales increase for BAQSIMI, while significantly expanding its proprietary pipeline.

Key takeaways
  • Q3 net revenues rose to $191.8 million, driven by strong performances in BAQSIMI and Primatene MIST.
  • BAQSIMI sales hit a record high of $53.6 million, an increase of 14% year-over-year, aided by enhanced sales execution.
  • The company secured U.S. and Canadian rights for three early-stage peptide candidates, broadening its pipeline with a market potential exceeding $60 billion.
  • FDA approval of iron sucrose injection (AMP-002) was achieved, contributing $2.4 million in sales during the quarter.
  • Amphastar is on track for multiple product launches in 2026 and 2027, positioning itself strategically in competitive therapeutic markets.
More info
Barnes Group Inc. logo
B
Barnes Group Inc.
B
Q3 2025
Reported:

Barrick Mining Corporation delivered exceptional third-quarter results, achieving record operating cash flow and free cash flow alongside a 25% increase in the base dividend, despite tragic safety incidents.

Key takeaways
  • Adjusted earnings per share and cash flow reached all-time highs, bolstered by a 4% increase in gold production.
  • Free cash flow surged by 274% quarter-over-quarter, leading to $598 million in share repurchases and record cash returns to shareholders.
  • The company launched a $1.5 billion share buyback program and increased its base dividend by 25% to 12.5 cents per share.
  • Operational reviews are underway to enhance safety and performance across all gold assets, heightened by recent safety concerns resulting in three fatalities.
  • Updated PEA indicates Fourmile is a potentially landmark gold discovery for the century.
More info
BCE Inc. logo
BC
BCE Inc.
BCE.TO
Q3 2025
Reported:

BCE delivered a solid Q3 2025 performance with significant reductions in postpaid churn and robust growth in AI-powered solutions, reaffirming its strategic priorities outlined in its recently launched three-year plan.

Key takeaways
  • Reported a second consecutive quarter of significant postpaid churn reduction, supported by enhanced customer service and innovative wireless plans.
  • Ziply Fiber, now included in BCE's results, exceeded financial expectations, with plans to expand its fiber network in the U.S. from 1.4 million homes to approximately 3 million by 2028.
  • AI-powered solutions revenue grew 34% year-over-year, highlighting the effectiveness of BCE’s strategic focus on technology and data sovereignty.
  • Product intensity increased 7% year-over-year, driven by growth in content subscriptions, with a target to further boost this by 25% over the next three years.
  • New partnership with AST SpaceMobile aims to enhance network connectivity across challenging geographic areas in Canada, with service launch expected in late 2026.
More info
CBAK Energy Technology, Inc. logo
CB
CBAK Energy Technology, Inc.
CBAT
Q3 2025
Reported:

CBAK Energy Technology posted robust Q3 results with a 36.5% revenue increase to $50.9 million, driven by strong performance from Hitrans and stabilization in its battery segment.

Key takeaways
  • Hitrans segment revenue surged 143.7% year-over-year to approximately $27.2 million, indicating recovery in raw material prices.
  • Battery business stabilized with revenue growth of 0.7%, bolstered by high demand for Model 32140 batteries; net income for this segment rose 122.7% to $4.53 million.
  • Consolidated net income attributable to shareholders soared 150-fold year-over-year to $2.65 million, reflecting improved profitability across segments.
  • New product lines launching in Dalian and an expansion at Nanjing are set to enhance production capacity and drive future revenue growth.
  • The company is pursuing overseas manufacturing but awaits clarity on China's export control policies, which could impact expansion timelines.
More info
Compugen Ltd. logo
CG
Compugen Ltd.
CGEN
Q3 2025
Reported:

Compugen reported strong fundamentals in Q3 2025, driven by its innovation in Fc reduced anti-TIGIT treatments and promising clinical developments aimed at redefining cancer therapy.

Key takeaways
  • Introduction of COM902, a fully owned Fc reduced anti-TIGIT monoclonal antibody, highlights Compugen's strategic advantage over Fc active competitors in clinical efficacy and safety.
  • Partnership with AstraZeneca on rilfrogostomy positions Compugen to benefit from a substantial commercial opportunity, with peak year revenue estimates exceeding $5 billion.
  • COM701, the only Fc reduced anti-PVRIG antibody in clinical development, targets unmet medical needs in platinum-sensitive ovarian cancer, enhancing Compugen's diverse pipeline.
  • Potential milestone payments of $758 million through the Gilead partnership on the innovative GS0321 program showcase significant financial upside.
  • Upcoming data readouts from key programs anticipated in 2026 could catalyze investment interest and market recognition for Compugen’s unique therapies.
More info
Daimler Truck Holding AG logo
DT
Daimler Truck Holding AG
DTG.DE
Q3 2025
Reported:

Daimler Truck reported a challenging Q3 2025, with revenue declining 13% year-over-year to EUR 11.5 billion amid a deepening downturn in North American markets, although European recovery trends showed promise.

Key takeaways
  • Industrial business revenue totaled EUR 10.6 billion with unit sales down 15% to 98,000.
  • Adjusted EBIT fell 40% to EUR 716 million, reflecting a sharp 60% profit drop in Trucks North America.
  • Strong demand for the Actros L drove a recovery in European heavy-duty market share to 19.1% in Q3.
  • Commitment to zero-emission vehicles remains strong, with market leadership in Europe at 33% year-to-date.
  • Free cash flow improved modestly to EUR 24 million, supporting a net industrial liquidity position of EUR 5.9 billion.
More info
Exchange Income Corporation logo
EI
Exchange Income Corporation
EIF.TO
Q3 2025
Reported:

Exchange Income Corporation reported record third-quarter results, achieving all-time highs across key financial metrics including revenue, adjusted EBITDA, and free cash flow. The successful integration of Canadian North supports positive forward momentum and cash flow expectations.

Key takeaways
  • Set all-time highs in revenue, adjusted EBITDA, and net earnings, underscoring robust operational performance.
  • Completed acquisition of Canadian North has bolstered market position and is on track for integration success.
  • Total leverage nearing historic lows enhances balance sheet flexibility post-convertible debenture redemption.
  • Demand for aerospace services driven by NATO defense spending and critical resource mining trends indicate strong growth prospects ahead.
  • Adjustments to cost structures and operational efficiencies underway across segments, aimed at optimizing profitability.
More info
Centrais Eletricas Brasileiras S.A. - Eletrobras logo
EL
Centrais Eletricas Brasileiras S.A. - Eletrobras
ELET3.SA
Q3 2025
Reported:

AXIA Energia reported a solid Q3 2025, underscored by a significant BRL 4.3 billion dividend announcement, supported by effective asset management and robust operational efficiencies despite a decline in net income year-over-year.

Key takeaways
  • Achieved record shareholder compensation with a total dividend payout of BRL 9.3 billion for the year, showcasing strong capital allocation strategy.
  • Successfully divested from non-core assets, including Eletronuclear and EMAE, while acquiring a majority stake in Tijoa Energia.
  • Revenue impacted by regulatory changes, yet EBITDA saw smaller fluctuations due to PMSO reductions and increased transmission earnings.
  • Increased competitiveness demonstrated through successful bidding for multiple auction lots, with total investments reaching BRL 17.4 billion since privatization.
  • Continued focus on enhancing customer engagement and operational efficiency, positioning for improved performance into 2026.
More info
Euronext N.V. logo
EN
Euronext N.V.
ENX.PA
Q3 2025
Reported:

Euronext achieved a robust performance in Q3 2025, marking its sixth consecutive quarter of double-digit revenue growth with a 10.6% year-on-year increase to EUR 438.1 million. The company also announced its inclusion in the CAC 40 Index, bolstering market liquidity.

Key takeaways
  • Non-volume-related revenue grew to 60% of total revenue, driven by strong growth in custody, settlement, and contributions from recent acquisitions.
  • Adjusted EBITDA climbed 12.6% year-on-year to EUR 276.7 million, with a margin increase to 63.2%.
  • Euronext upgraded its 2025 underlying operating cost guidance to EUR 660 million, reflecting disciplined cost management.
  • A EUR 250 million share repurchase program was announced, expected to be executed between November 2025 and Q1 2026.
  • Euronext is pursuing consolidation through its offer for ATHEX Group, aiming for EUR 12 million in annual cash synergies by the end of 2028.
More info
Evolus, Inc. logo
EO
Evolus, Inc.
EOLS
Q3 2025
Reported:

Evolus delivered a strong third quarter with a 13% revenue increase driven by robust demand for Jeuveau and promising early results from the Evolysse launch, positioning the company for sustainable profitability by 2026.

Key takeaways
  • Jeuveau unit sales grew consistently, achieving a 14% share of the U.S. market.
  • Evolysse generated $5.7 million in revenue during its third quarter, marking the strongest debut for a HA filler in over a decade.
  • The Evolus Rewards program saw total redemptions rise 34%, reinforcing consumer loyalty with 70% of members being repeat customers.
  • The company remains focused on efficiency as it prepares to bundle products, encouraging cross-selling while expanding its customer base to over 17,000 accounts.
More info
Exodus Movement, Inc. logo
EX
Exodus Movement, Inc.
EXOD
Q3 2025
Reported:

Exodus Movement, Inc. reported a strong Q3 2025 with revenues reaching $30.3 million, reflecting a 51% year-over-year growth, bolstered by rising digital asset prices and strategic partnerships.

Key takeaways
  • Revenue increased significantly, driven by a favorable digital asset market and growing B2B swap partnerships, totaling $1.75 billion in quarterly swap volume.
  • The company announced the acquisition of Grateful, enhancing its stablecoin payment capabilities and expanding its merchant checkout experience.
  • Monthly active users remained stable at 1.5 million, with a 20% increase in quarterly funded users, indicating strong user retention and engagement.
  • Non-exchange related revenue surpassed 10% for the first time, highlighting growth in staking and ExoPay products.
  • Exodus is strategically positioning itself for future innovations in real-world asset tokenization and potential Bitcoin dividends for shareholders.
More info
freenet AG logo
FN
freenet AG
FNTN.DE
Q3 2025
Reported:

The company demonstrated steady growth in Q3, successfully increasing postpaid customer numbers and adjusted EBITDA while confirming its 2025 guidance amidst strategic acquisitions and optimized marketing initiatives.

Key takeaways
  • Adjusted EBITDA rose by 1.6% year-to-date and 4% for the last quarter, driven in part by waipu.tv's growth.
  • Postpaid customer base increased by 190,000 in the first nine months, exceeding expectations.
  • Acquisition of mobilezone enhances sales capabilities and competitive positioning in the market.
  • Marketing strategy shifted to performance-based models, improving conversion rates and user experience on web platforms.
  • Free cash flow grew by 2.8% year-to-date, signaling strong financial health despite a one-off tax impact.
More info
Genmab A/S logo
GM
Genmab A/S
GMAB
Q3 2025
Reported:

Genmab reported strong financial results for the first nine months of 2025, with total revenue increasing by 21% and operating profit up by 52%, driven by strategic investments and a robust late-stage pipeline.

Key takeaways
  • Proposed acquisition of Merus expected to enhance Genmab's portfolio and accelerate revenue diversification.
  • Strong performance of EPKINLY and Rina-S, with promising clinical data presented, including an upcoming Phase III trial for Rina-S in endometrial cancer.
  • Financial position remains solid with $3.4 billion in cash, allowing for continued investment in high-impact programs.
  • Epcoritamab is set for potential approval in second-line follicular lymphoma, with substantial data support for its expanded use in upcoming ASH presentations.
More info
Global Ship Lease, Inc. logo
GS
Global Ship Lease, Inc.
GSL
Q3 2025
Reported:

Global Ship Lease reported strong performance driven by a robust charter portfolio, resulting in a significant increase in contracted revenues and a notable dividend hike amidst ongoing geopolitical uncertainties.

Key takeaways
  • Added $778 million in contracted revenues through nine months of 2025 with full contract coverage for the remainder of 2025, 96% for 2026, and 74% for 2027.
  • Increased annualized dividend by 19% to $2.50 per share, representing a 67% increase from the previous year.
  • Achieved strong credit ratings, bolstered by a healthier balance sheet and an investment-grade rating on U.S. private placement notes.
  • Cash position of $562 million provides flexibility for capital expenditures and strategic investments amidst market volatility.
  • Reduced financial leverage to 2.5 times, down from over 8 times, while maintaining competitive breakeven rates.
More info
IonQ Inc. Common Stock logo
IO
IonQ Inc. Common Stock
IONQ
Q3 2025
Reported:

IonQ's Q3 2025 results surpassed expectations, achieving a remarkable 222% year-on-year revenue growth and the largest quarterly revenue beat in the company's history.

Key takeaways
  • Revenue exceeded guidance by 37%, highlighting strong commercial traction and demand for quantum solutions.
  • Successfully launched the #AQ 64 Tempo system three months ahead of schedule, enhancing technical capabilities.
  • Closed the acquisition of Oxford Ionics and bolstered its leadership with notable hires, including former intelligence and military officials.
  • Demonstrated significant advancements in quantum technology, achieving a world record 2-qubit gate fidelity of 99.99%.
  • Continued strategic expansion into quantum networking and sensing, aimed at enhancing service offerings and driving future growth.
More info
Kamada Ltd. logo
KM
Kamada Ltd.
KMDA
Q3 2025
Reported:

Kamada Ltd. delivered robust performance in Q3 2025, achieving an 11% year-over-year revenue growth and a significant 35% increase in adjusted EBITDA, reinforcing its full-year guidance.

Key takeaways
  • Total revenues for the first nine months reached $135.8 million, with adjusted EBITDA at $34.2 million, highlighting strong operational efficiency.
  • The company is maintaining its 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million.
  • Growth driven by increased demand for products like KedRAB and GALASIA, alongside strategic marketing initiatives for Cytogam and new biosimilars.
  • Active due diligence in potential M&A opportunities, expected to enhance product portfolio and accelerate commercial growth.
  • Progress on plasma collection centers in Houston and San Antonio, anticipated to generate $16 million to $20 million annually at full capacity.
More info
Lundin Gold Inc. logo
LU
Lundin Gold Inc.
LUG.TO
Q3 2025
Reported:

Lundin Gold delivered a robust Q3 2025 performance, achieving record production levels and significant revenue growth amidst rising gold prices, while strategically expanding its exploration efforts.

Key takeaways
  • Produced 122,000 ounces of gold, with an average mill throughput of 5,264 tonnes per day, reaffirming annual guidance of 490,000 to 525,000 ounces.
  • Revenue soared 38% year-over-year to $447 million, with net income reaching a record high of $208 million, a 53% increase.
  • Declared a quarterly dividend of $0.80 per share, reflecting a robust cash flow and increased variable component to align with free cash flow performance.
  • Expanded exploration program from 80,000 meters to a minimum of 120,000 meters, highlighting strong potential across multiple sites.
  • All-in sustaining costs per ounce sold remained competitive at $1,036, with a substantial ASIC margin of 71% driven by higher gold prices.
More info
monday.com Ltd. Ordinary Shares logo
MN
monday.com Ltd. Ordinary Shares
MNDY
Q3 2025
Reported:

monday.com Ltd. delivered robust Q3 FY 2025 results, achieving a record non-GAAP operating profit while significantly expanding its customer base and product offerings, positioning the company favorably for its long-term revenue targets.

Key takeaways
  • Total revenue reached $317 million, a 26% increase year-over-year, driven by strong performance in larger customer segments.
  • Recorded net additions of over 100,000 customers, exceeding 500,000 paying customers in total, highlighting the effectiveness of their go-to-market strategy.
  • Operating income reached a record $47.5 million, with an operating margin of 15%, underscoring improved operational efficiency.
  • New product revenues surpassed 10% of total ARR, ahead of their 2025 goal, reflecting successful multi-product and AI-driven strategies.
  • Gross margin maintained at 90%, with expectations to remain in the high 80s in the medium to long term.
More info
Topgolf Callaway Brands Corp. Common Stock logo
MO
Topgolf Callaway Brands Corp. Common Stock
MODG
Q3 2025
Reported:

Topgolf Callaway Brands reported strong Q3 2025 results, exceeding expectations in revenue and EBITDA driven by robust performance in its Golf Equipment and Topgolf segments, while maintaining positive momentum in brand innovation and consumer engagement.

Key takeaways
  • Revenue rose year-over-year across both Golf Equipment and Topgolf segments, supported by effective execution and favorable market conditions.
  • Golf Equipment segment saw a 22.6% market share in golf balls, indicating strong brand positioning and consumer preference.
  • Positive same venue sales at Topgolf mark a successful transition to overall traffic growth, following midyear value initiatives.
  • Tariffs negatively impacted margins with a forecasted total expense of approximately $40 million for the year, prompting cost management and efficiency efforts.
  • Strategic product innovations, including the award-winning Elyte Triple Diamond Driver and new TRI-HOT putters, bolster market competitiveness and brand leadership.
More info
ArcelorMittal logo
MT
ArcelorMittal
MT
Q3 2025
Reported:

ArcelorMittal reports robust Q3 performance, achieving an EBITDA per tonne of $111—25% above historical averages—highlighting strategic growth and asset optimization efforts.

Key takeaways
  • Strong EBITDA margin indicates effective asset optimization and ongoing structural improvements, with a projected $0.7 billion EBITDA enhancement for 2025.
  • Free cash flow remains healthy at approximately $0.5 billion year-to-date, despite substantial investments in growth projects.
  • Positive business outlook supported by the European Commission’s proposed trade tools, expected to bolster capacity utilization in the steel sector.
  • ArcelorMittal continues to focus on high-margin electrical steels and renewable energy, positioning for future growth opportunities.
  • Capital return policies have resulted in a 16% compound annual dividend growth, underlining financial strength and shareholder commitment.
More info
ArcelorMittal logo
MT
ArcelorMittal
MT.AS
Q3 2025
Reported:

ArcelorMittal reported a strong third quarter in 2025, demonstrating structural improvements with EBITDA per tonne significantly above historical averages while maintaining positive free cash flow despite substantial investment in growth initiatives.

Key takeaways
  • EBITDA per tonne reached $111, marking a 25% increase above historical margins, driven by asset optimization and strategic projects.
  • Positive free cash flow of approximately $0.5 billion generated during the first nine months, even after $1 billion investment in growth projects.
  • The outlook for the business is improving, aided by new European trade proposals expected to enhance capacity utilization in the sector.
  • Continued capital return strategies have led to a compounded 16% growth in dividends over the past five years and significant equity repurchases.
  • Plans to capture $0.7 billion in structural EBITDA improvement by year-end, with a medium-term target of $2.1 billion remaining intact.
More info
Pagaya Technologies Ltd. Class A Ordinary Shares logo
PG
Pagaya Technologies Ltd. Class A Ordinary Shares
PGY
Q3 2025
Reported:

Pagaya Technologies Ltd. reported strong third quarter results, achieving consistent GAAP net income profitability and setting an annualized exit rate of over $120 million, reflecting robust growth and strategic operational execution.

Key takeaways
  • Record quarterly network volume reached $2.8 billion, with a 12% sequential application flow growth, indicating strong scalability.
  • Successful expansion of partner relationships, with the onboarding of up to eight new partners, maximizing product engagement across diverse asset classes.
  • Issued $1.8 billion in ABS across multiple transactions, bolstering capital efficiency and expanding funding diversity.
  • Consistent application-to-funding conversion rate held at 1%, demonstrating effective pipeline management and solid conversion strategies.
  • Progress towards multi-year contracts with key partners, enhancing long-term revenue stability and positioning Pagaya as a fundamental utility for U.S. lenders.
More info
uniQure N.V. logo
QU
uniQure N.V.
QURE
Q3 2025
Reported:

uniQure N.V. delivered strong top-line results from its pivotal Phase 1/2 study of AMT-130, marking a significant milestone in Huntington's disease treatment, although FDA feedback introduces uncertainty regarding the expected BLA submission timeline.

Key takeaways
  • AMT-130 demonstrated a statistically significant 75% slowing of disease progression over three years, meeting pivotal study endpoints.
  • The FDA's recent feedback has raised concerns over the adequacy of AMT-130's evidence for a BLA submission, leading to uncertainty regarding the submission timeline.
  • In addition to Huntington's, uniQure is advancing AMT-260 for epilepsy, with active recruitment of clinical sites and initial positive data expected next year.
  • Results from the Phase 1/2a trial of AMT-191 for Fabry disease show promising enzyme activity, with one patient successfully withdrawing from enzyme replacement therapy.
  • uniQure remains committed to engaging with the FDA to expedite the path forward for AMT-130 despite the recent setbacks.
More info
FreightCar America, Inc. logo
RA
FreightCar America, Inc.
RAIL
Q3 2025
Reported:

FreightCar America reported a stellar Q3 2025, with revenue surging 42% year-over-year and a record adjusted EBITDA of $17 million, reflecting robust operational improvements and strategic focus on high-value railcar solutions.

Key takeaways
  • Achieved a gross margin of 15.1% and an adjusted EBITDA margin of 10.6%, both improved by over 100 basis points year-over-year.
  • Backlog remains strong at 2,750 units valued at approximately $222 million, with ongoing demand for conversions and retrofits offsetting overall industry softness.
  • The company continues to enhance operational efficiency through innovations like the TrueTrack process, promoting quality and on-time deliveries.
More info
RadNet, Inc. logo
RD
RadNet, Inc.
RDNT
Q3 2025
Reported:

RadNet delivered outstanding third-quarter results, with record revenues and adjusted EBITDA outperforming internal forecasts, driven by robust demand for advanced imaging and improved reimbursement rates.

Key takeaways
  • Total revenue rose 13.4% and adjusted EBITDA increased 15.2% year-over-year, achieving a 26 basis point margin improvement.
  • Advanced imaging procedures grew by 13% overall, with a shift towards higher-margin services contributing to enhanced profitability.
  • Successful implementation of AI technology and strategic acquisitions, like iCAD, are significantly expanding service capabilities and operational efficiencies.
  • Enhanced reimbursement rates from capitated and commercial payers underline RadNet's value proposition as a cost-effective alternative to hospital imaging.
  • Full-year 2025 guidance for revenue and adjusted EBITDA has been increased due to strong performance and positive trends continuing into Q4.
More info
Sacyr, S.A. logo
SC
Sacyr, S.A.
SCYR.MC
Q3 2025
Reported:

Sacyr's Q3 2025 results reflect robust growth and operational efficiency, with revenue increasing by 5% to EUR 3.412 billion and net profit soaring 81% (excluding divestments) to EUR 134 million.

Key takeaways
  • EBITDA rose by 7% to EUR 1.018 billion, enhancing the EBITDA margin and showcasing improved operational efficiency.
  • Operating cash flow surged by 11% to EUR 890 million, indicating strong cash generation ability.
  • Sacyr secured four new concession awards across Italy, Chile, and Paraguay, reinforcing its strategic position and backlog.
  • The company received an investment-grade rating from Morningstar DBRS, expected to lower financing costs and broaden funding sources.
  • Cash dividends maintained at EUR 0.045 per share, aligned with the strategic plan’s commitment to returning at least EUR 225 million to shareholders.
More info
Saturn Oil & Gas Inc. logo
SO
Saturn Oil & Gas Inc.
SOIL.TO
Q3 2025
Reported:

Saturn delivered robust Q3 2025 results, with production exceeding guidance amid strategic capital reallocations and successful tuck-in acquisitions.

Key takeaways
  • Q3 production averaged over 41,100 BOE/day, surpassing both guidance and analyst expectations.
  • Operating costs came in at $19.24 per BOE, below the targeted $20, showcasing improved capital efficiency.
  • The company reduced its 2025 development budget by 18% to $255 million, redirecting funds towards high-return tuck-in acquisitions, increasing stockholder value.
  • Recent acquisitions added approximately 5,400 BOE/day of production capacity, with significant opportunities for optimization and cost synergies.
  • Share buyback initiatives have returned about $36 million to shareholders, enhancing equity value while increasing production per share by 22%.
More info
Solvay SA logo
SO
Solvay SA
SOLB.BR
Q3 2025
Reported:

Solvay's third quarter results reflect ongoing challenges with macroeconomic conditions, yet the company showcases resilience through strategic operational enhancements and successful CO2 emissions rights sales.

Key takeaways
  • **Strong EBITDA from Strategic Moves:** Generated EUR 40 million in EBITDA from selling a portion of CO2 emission rights, part of a broader strategy that may be repeated in the future.
  • **Operational Excellence Program:** On track to deliver EUR 350 million in cost savings by 2028, leveraging digital advancements and condition-based maintenance to enhance efficiency.
  • **Market Pressures Persist:** Continued difficulties in the soda business due to Chinese overcapacity and tariffs impacting export markets, leading to reduced production in European facilities.
  • **Transformation Initiatives:** Implementing a digital-first approach across operations with over 4,500 sensors installed for predictive maintenance, demonstrating commitment to both efficiency and sustainability.
  • **Cultural Shift Towards Safety:** Ongoing focus on evolving safety culture within operations, reinforcing that safety remains the company's top priority amidst operational challenges.
More info
TELUS Corporation logo
T.
TELUS Corporation
T.TO
Q3 2025
Reported:

TELUS reported robust Q3 2025 performance with record customer growth and strong financial results, underscoring its dominant position in the telecommunications industry.

Key takeaways
  • Achieved 288,000 total mobile and fixed customer additions, marking a 5% year-over-year growth.
  • TTech EBITDA grew 3%, while TELUS Health experienced remarkable revenue growth of 18% and adjusted EBITDA growth of 24%.
  • Sustained industry-leading postpaid mobile phone churn of 0.91%, reflecting strong customer loyalty.
  • Completed the acquisition of TELUS Digital, projecting annualized cash synergies between $150 million and $200 million by 2026.
  • Significant potential in AI services, aiming for $2 billion in external client revenue by 2028.
More info
TC Energy Corporation logo
TR
TC Energy Corporation
TRP.TO
Q3 2025
Reported:

TC Energy delivered strong performance in Q3 2025, with an 8% year-over-year increase in comparable EBITDA and a new $700 million in growth projects, positioning the company for sustainable growth amidst rising energy demand.

Key takeaways
  • Comparable EBITDA rose 8% year-over-year for the first nine months of 2025.
  • Successfully placed $8 billion of assets into service, tracking 15% under budget.
  • Announced an additional $700 million in growth projects, increasing total sanctioned projects to $5.1 billion over the last year.
  • Expecting net capital expenditures for 2025 to land at the low end of the $5.5 billion to $6 billion range.
  • Enhanced regulatory support in Canada and the U.S. is driving demand for natural gas and infrastructure projects, bolstering long-term growth prospects.
More info
USA Rare Earth Inc logo
US
USA Rare Earth Inc
USAR
Q3 2025
Reported:

USA Rare Earth reported strong strategic advancements in Q3 2025, underscoring its commitment to reshaping the rare earth supply chain amidst geopolitical challenges.

Key takeaways
  • Successful acquisition of Less Common Metals enhances revenue potential and establishes a fully integrated rare earth supply chain.
  • Launched an apprenticeship program to address the skilled talent shortage in domestic metal production.
  • Progress made in recycling technology, with pilot-scale testing of swarf recycling scheduled for Q1 2026.
  • Initiated pre-feasibility study for the Round Top development project, targeting completion by Q3 2026.
  • Strong pipeline for magnet sales and ongoing advancements in proprietary rare earth extraction and purification technologies.
More info
Village Farms International, Inc. logo
VF
Village Farms International, Inc.
VFF
Q3 2025
Reported:

Village Farms International reported strong third-quarter results, marked by a 21% increase in consolidated net sales year-over-year and record adjusted EBITDA margins, reinforcing its position as a leader in the cannabis market.

Key takeaways
  • Consolidated net sales grew 21% year-over-year, reaching a record $64.1 million in the Canadian cannabis segment.
  • Net income from continuing operations increased to $10.8 million, up nearly 10% sequentially from the previous quarter.
  • Adjusted EBITDA hit a new high of $20.7 million, representing an adjusted EBITDA margin of 31%.
  • International medical cannabis sales surged over 750% year-over-year, highlighting rapid growth in Germany and anticipated expansion into new markets.
  • A 40 metric ton expansion project is underway, expected to increase annual production capacity by approximately 33% by early 2027.
More info
Wave Life Sciences Ltd. logo
WV
Wave Life Sciences Ltd.
WVE
Q3 2025
Reported:

Wave Life Sciences reported strong advancements in its clinical pipeline during Q3 2025, particularly with WVE-007 demonstrating significant potential for weight loss and improved metabolic health through its unique mechanism of action.

Key takeaways
  • WVE-007 showed impressive dose-dependent reductions in activin E of up to 85%, indicating strong efficacy in its first clinical trial cohorts.
  • Enrollment in the Enlight trial is progressing well, with over 70 participants and a plan to report on more than 100 by 2026.
  • Positive feedback from recent presentations at Obesity Week highlights industry recognition for WVE-007's potential to offer a convenient treatment alternative to current therapies.
  • WVE-006 is advancing as a potential first-in-class treatment for AAT deficiency, differentiating itself through its simple subcutaneous dosing regimen.
  • The company anticipates delivering multiple key updates in the coming months, reflecting on early impacts on weight loss and metabolic health markers.
More info

📊 Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector